Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study

To treated with electrochemotherapy (ECT) a prospective case series of patients with liver cirrhosis and Vp3-Vp4- portal vein tumor thrombus (PVTT) from hepatocellular carcinoma (HCC), in order to evaluate the feasibility, safety and efficacy of this new non thermal ablative technique in those patients

A Fit to the Available <i>e</i>⁺<i>e</i>⁻ → <inline-formula><math display="inline"><semantics><mrow><msubsup><mi mathvariant="sans-serif">Λ</mi><mi>c</mi><mo>+</mo></msubsup><msubsup><mover accent="true"><mi mathvariant="sans-serif">Λ</mi><mo>¯</mo></mover><mi>c</mi><mo>−</mo></msubsup></mrow></semantics></math></inline-formula> Cross Section Data Nearby Production Threshold by Means of a Strong Correction to the Coulomb Enhancement Factor

There are two available sets of data on the e+e−→Λc+Λ¯c− cross section at energies close to the production threshold, collected by the Belle and by the BESIII Collaborations. The measurement of the former, performed by means of the initial state radiation technique, is compatible with the presence of a resonance, called ψ(4660), observed also in other final states. On the contrary, the latter is measured an almost flat and hence non-resonant cross section in the energy region just above the production threshold, but the data stop before the possible rise in the cross section for the resonant production. We propose an effective model to describe the behavior of the data near this threshold, which is based on a Coulomb-like enhancement factor due to the strong interaction among the final state particles. In the framework of this model, it is possible to describe both datasets

Operation of the CGEM Detector

A ten years extension of the data taking of BESIII experiment, recently approved, motivated an upgrade program both for the leptonic collider BEPCII and for some of the sub-detectors of the spectrometer. BESIII is a multipurpose spectrometer optimized for physics in the charm-τ energy region. In particular, the current inner drift chamber is suffering from aging and the proposal is to replace it with a detector based on Cylindrical Gas Electron Multiplier (CGEM) technology to improve both the secondary vertex reconstruction and the radiation tolerance. The CGEM Inner Tracker will be composed of three coaxial layers of cylindrical triple GEMs, operating in an Ar + iC4H10 (90:10) gas mixture with field and gain optimized to maximize the spatial resolution. The new detector is readout with innovative TIGER electronics produced in 110 nm CMOS technology. A cosmic telescope instrumented with two out of three layers is in operation in Beijing since January 2020, remotely controlled by Italian groups due to the pandemic situation. A dedicated readout chain was developed for data acquisition. In this paper, the general status of the project will be presented with a particular focus on the preliminary results from the cosmic data taking and future plans

Management of myocardial revascularization in patients with stable coronary artery disease undergoing transcatheter aortic valve implantati

Background:The best management of stable coronary artery disease (CAD) in patients undergoing transcatheter aortic valve implantation (TAVI) is still unclear due to the marked inconsistency of the available evidence. Methods:The REVASC-TAVI registry (Management of Myocardial Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation With Coronary Artery Disease) collected data from 30 centers worldwide on patients undergoing TAVI who had significant, stable CAD at preprocedural work-up. For the purposes of this analysis, patients with either complete or incomplete myocardial revascularization were compared in a propensity score matched analysis, to take into account of baseline confounders. The primary and co-primary outcomes were all-cause death and the composite of all-cause death, stroke, myocardial infarction, and rehospitalization for heart failure, respectively, at 2 years. Results:Among 2407 patients enrolled, 675 pairs of patients achieving complete or incomplete myocardial revascularization were matched. The primary (21.6% versus 18.2%, hazard ratio, 0.88 [95% CI, 0.66-1.18]; P=0.38) and co-primary composite (29.0% versus 27.1%, hazard ratio, 0.97 [95% CI, 0.76-1.24]; P=0.83) outcome did not differ between patients achieving complete or incomplete myocardial revascularization, respectively. These results were consistent across different prespecified subgroups of patients (&lt; or &gt;75 years of age, Society of Thoracic Surgeons score &gt; or &lt;4%, angina at baseline, diabetes, left ventricular ejection fraction &gt; or &lt;40%, New York Heart Association class I/II or III/IV, renal failure, proximal CAD, multivessel CAD, and left main/proximal anterior descending artery CAD; all P values for interaction &gt;0.10). Conclusions:The present analysis of the REVASC-TAVI registry showed that, among TAVI patients with significant stable CAD found during the TAVI work-up, completeness of myocardial revascularization achieved either staged or concomitantly with TAVI was similar to a strategy of incomplete revascularization in reducing the risk of all cause death, as well as the risk of death, stroke, myocardial infarction, and rehospitalization for heart failure at 2 years, regardless of the clinical and anatomical situations

Comparison of different percutaneous revascularisation timing strategies in patients undergoing transcatheter aortic valve implantation.

BACKGROUND The optimal timing to perform percutaneous coronary interventions (PCI) in transcatheter aortic valve implantation (TAVI) patients remains unknown. AIMS We sought to compare different PCI timing strategies in TAVI patients. METHODS The REVASC-TAVI registry is an international registry including patients undergoing TAVI with significant, stable coronary artery disease (CAD) at preprocedural workup. In this analysis, patients scheduled to undergo PCI before, after or concomitantly with TAVI were included. The main endpoints were all-cause death and a composite of all-cause death, stroke, myocardial infarction (MI) or rehospitalisation for congestive heart failure (CHF) at 2 years. Outcomes were adjusted using the inverse probability treatment weighting (IPTW) method. RESULTS A total of 1,603 patients were included. PCI was performed before, after or concomitantly with TAVI in 65.6% (n=1,052), 9.8% (n=157) or 24.6% (n=394), respectively. At 2 years, all-cause death was significantly lower in patients undergoing PCI after TAVI as compared with PCI before or concomitantly with TAVI (6.8% vs 20.1% vs 20.6%; p<0.001). Likewise, the composite endpoint was significantly lower in patients undergoing PCI after TAVI as compared with PCI before or concomitantly with TAVI (17.4% vs 30.4% vs 30.0%; p=0.003). Results were confirmed at landmark analyses considering events from 0 to 30 days and from 31 to 720 days. CONCLUSIONS In patients with severe aortic stenosis and stable coronary artery disease scheduled for TAVI, performance of PCI after TAVI seems to be associated with improved 2-year clinical outcomes compared with other revascularisation timing strategies. These results need to be confirmed in randomised clinical trials

Management of Myocardial Revascularization in Patients With Stable Coronary Artery Disease Undergoing Transcatheter Aortic Valve Implantation.

BACKGROUND The best management of stable coronary artery disease (CAD) in patients undergoing transcatheter aortic valve implantation (TAVI) is still unclear due to the marked inconsistency of the available evidence. METHODS The REVASC-TAVI registry (Management of Myocardial Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation With Coronary Artery Disease) collected data from 30 centers worldwide on patients undergoing TAVI who had significant, stable CAD at preprocedural work-up. For the purposes of this analysis, patients with either complete or incomplete myocardial revascularization were compared in a propensity score matched analysis, to take into account of baseline confounders. The primary and co-primary outcomes were all-cause death and the composite of all-cause death, stroke, myocardial infarction, and rehospitalization for heart failure, respectively, at 2 years. RESULTS Among 2407 patients enrolled, 675 pairs of patients achieving complete or incomplete myocardial revascularization were matched. The primary (21.6% versus 18.2%, hazard ratio' 0.88 [95% CI, 0.66-1.18]; P=0.38) and co-primary composite (29.0% versus 27.1%, hazard ratio' 0.97 [95% CI, 0.76-1.24]; P=0.83) outcome did not differ between patients achieving complete or incomplete myocardial revascularization, respectively. These results were consistent across different prespecified subgroups of patients (75 years of age, Society of Thoracic Surgeons score > or or 0.10). CONCLUSIONS The present analysis of the REVASC-TAVI registry showed that, among TAVI patients with significant stable CAD found during the TAVI work-up, completeness of myocardial revascularization achieved either staged or concomitantly with TAVI was similar to a strategy of incomplete revascularization in reducing the risk of all cause death, as well as the risk of death, stroke, myocardial infarction, and rehospitalization for heart failure at 2 years, regardless of the clinical and anatomical situations